期刊文献+

正确认识和掌握高度近视黄斑病变的诊疗方法,减少高度近视患者视功能损害 被引量:8

High myopia-related macular lesions: diagnosis and treatment
原文传递
导出
摘要 以近视眼中心凹劈裂、黄斑裂孔及黄斑裂孔性视网膜脱离、近视性脉络膜新生血管为代表的高度近视黄斑病变是影响高度近视患者视功能的主要原因之一。光相干断层扫描检查有助于提升高度近视黄斑病变的认知水平。选择合适的手术时机,解除玻璃体后皮质和内界膜对视网膜的牵拉,有利于恢复视网膜的弹性,使近视眼中心凹劈裂消失,促进黄斑裂孔的闭合和视网膜复位;而抗新生血管药物与光动力疗法和(或)糖皮质激素联合应用,则是治疗近视性脉络膜新生血管的发展方向。正确认识和掌握高度近视黄斑病变的诊疗方法和时机,采取针对性的干预措施,使其能够得到合理有效的治疗,是进一步减少高度近视患者视功能损害的关键。 High myopia is frequently associated with retinal degenerative changes (such as myopic foveoschisis, macular hole and its related retinal detachment, and choroidal neovascularization) which are the major causes of visual loss in high myopic eyes. Optical coherence tomography may help us to understand the macular lesions in high myopia. Peeling of internal limiting membrane and removal of posterior vitreous cortex at an appropriate time, are believed to facilitate restoring the retinal flexibility and resolution of myopic foveoschisis, and promote the macular hole closure and retinal reattachment. Antiangiogenesis treatment combined with photodynamic therapy and (or) corticosteroid therapy are the future options to treat myopic choroidal neovascularization. Correctly understanding and mastering the methods and timing of diagnosis and treatment of high myopia-related macular degeneration, and taking targeted interventions to enable patients to be rational and effective treated, are the keys to further reduce the damage of visual function in patients with high myopia.
作者 赵培泉 许宇
出处 《中华眼底病杂志》 CAS CSCD 北大核心 2009年第5期327-330,共4页 Chinese Journal of Ocular Fundus Diseases
关键词 近视 退行性/并发症 近视 退行性/诊断 近视 退行性/外科学 述评 Myopia, degenerative/complications Myopia, degenerative/diagnosis Myopia, degenerative/surgery Editorial
  • 相关文献

参考文献46

  • 1Tokoro T. Criteria for diagnosis of pathologic myopia//Tokoro T. Atlas of posterior fundus changes in pathologic myopia. Tokyo: Springer Verlag, 1998:1-2.
  • 2Sperduto RD, Seigel D, Roberts J, et al. Prevalence of myopia in the United States. Arch Opthalmol, 1983,101: 405-407.
  • 3Tokoro T. On the definition of pathologic myopia in group studies. Acta Ophthalmol, 1988, 185(suppl) =107-108.
  • 4Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol, 1983,67:209 -213.
  • 5Phillips CI. Retinal detaehment at the posterior pole. Br J Ophthalmol, 1958,42 : 749-753.
  • 6Phillips CI, Dobbie JG. Posterior staphyloma and retinal detachment. AmJ Ophthalmol, 1963,45:332-335.
  • 7Takano M, Kishi S. Foveal retinosehisis and retinal detachment in severely myopic eyes with posterior staphyloma. Am J Ophthalmol, 1999,128: 472-476.
  • 8Tano Y. Pathologic myopia: where are we now? Am J Opthalmol, 2002,134 :645-660.
  • 9Benhamou N, Massin P, Haouchine B, et al. Macular retinoschisis in highly myopic eyes. Am J Ophthalmol, 2002, 133:794-800.
  • 10Shimada N, Ohno-Matsui K, Yoshida T. Progression from maeular retinoschisis to retinal detachment in highly myopic eyes is associated with outer lamellar hole formation. Br J Ophthalmol, 2008,92 : 762-764.

二级参考文献15

  • 1Spaide RF, Laud K, Fine HF, et al.Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina, 2006,26 : 383-390.
  • 2Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina, 2006,26 : 495-511.
  • 3Avery R, Pieramici DJ, Rabena MD, et al. lntravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 2006,113 : 363-372.
  • 4Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol, 2006, 142:1-9.
  • 5Costa RA, Jorqe R, Calucci D, et al. lntravitreal bevacizumab for choroidal neovascularization caused by AMD (IbeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci,2006, 47:4569-4578.
  • 6Rosenfeld PJ, Rich RM, Lalwani GA, et al. Ranibizumab : phase Ⅲ clinical trial results. Ophthalmol Clin North Am, 2006, 19: 361-372.
  • 7Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group: pegaptanib for neovascular agerelated macular degeneration. N Engl J Med, 2004,351:2805-2816.
  • 8Verteporfin in photodynamic therapy (VIP) study group. Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin : 1 year results of a randomized clinical trial. Ophthalmology,2001,108:841-852.
  • 9Treatment of age-related macular degeneration with photodynamic therapy ( TAP ) study group. Photodynamic therapy of subfoveal choroidal neovaseularization in age-related macular degeneration with verteportin: one-year results of 2 randomized clinical trials- TAP report. Arch Ophthalmol, 1999,117 : 1329-1345.
  • 10Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal Neovascularisation:a 10 year follow-up. Ophthalmology, 2003, 110:1297-1305.

共引文献18

同被引文献94

引证文献8

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部